Safety and efficacy on TAS-102 monotherapy in clinical practice in patients with metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Kotani, Daisuke [1 ]
Shitara, Kohei [1 ]
Fukuoka, Shota [1 ]
Bando, Hideaki [1 ]
Okamoto, Wataru [1 ]
Kojima, Takashi [1 ]
Doi, Toshihiko [1 ]
Yoshino, Takayuki [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ISS1-1-3
引用
收藏
页码：72 / 72
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of TAS-102 in Clinical Practice of Salvage Chemotherapy for Metastatic Colorectal Cancer
    Arita, Shuji
    Shirakawa, Tsuyoshi
    Matsushita, Yuzo
    Shimokawa, Hozumi Kumagai
    Hirano, Gen
    Makiyama, Akitaka
    Shibata, Yoshihiro
    Tamura, Shingo
    Esaki, Taito
    Mitsugi, Kenji
    Ariyama, Hiroshi
    Kusaba, Hitoshi
    Akashi, Koichi
    Baba, Eishi
    ANTICANCER RESEARCH, 2016, 36 (04) : 1959 - 1966
  • [2] Safety and efficacy on TAS-102 monotherapy in patients with metastatic colorectal cancer according to previous regorafenib
    Kotani, D.
    Shitara, K.
    Fukuoka, S.
    Kuboki, Y.
    Bando, H.
    Okamoto, W.
    Kojima, T.
    Doi, T.
    Ohtsu, A.
    Yoshino, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S364 - S365
  • [3] Factors associated with efficacy of TAS-102 in patients with refractory metastatic colorectal cancer (mCRC).
    Grell, Peter
    Dvorak, Josef
    Vocka, Michal
    John, Stanislav
    Tuskova, Helena
    Buchler, Tomas
    Petruzelka, Lubos B.
    Vyzula, Rostislav
    Obermannova, Radka
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [4] Safety and efficacy of trifluridine/tipiracil (TAS-102) plus bevacizumab in clinical practice for patients with refractory metastatic colorectal cancer
    Kotani, D.
    Kuboki, Y.
    Yasuda, K.
    Nakamura, Y.
    Kawazoe, A.
    Bando, H.
    Taniguchi, H.
    Shitara, K.
    Yoshino, T.
    ANNALS OF ONCOLOGY, 2018, 29 : 34 - 34
  • [5] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Sugiura, Kiyoaki
    Seo, Yuki
    Takahashi, Takayuki
    Tokura, Hideyuki
    Ito, Yasuhiro
    Tanaka, Motomu
    Kishida, Norihiro
    Nishi, Yusuke
    Onishi, Yoshihiko
    Aoki, Hikaru
    BMC GASTROENTEROLOGY, 2021, 21 (01)
  • [6] Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
    Kiyoaki Sugiura
    Yuki Seo
    Takayuki Takahashi
    Hideyuki Tokura
    Yasuhiro Ito
    Motomu Tanaka
    Norihiro Kishida
    Yusuke Nishi
    Yoshihiko Onishi
    Hikaru Aoki
    BMC Gastroenterology, 21
  • [7] Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer
    Abrahao, Ana Beatriz Kinupe
    Ko, Yoo-Joung
    Chan, Kelvin K.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Efficacy, tolerability, and manageability of TAS-102 plus bevacizumab for metastatic colorectal cancer patients in clinical practice.
    Ishikawa, Hideki
    Suzuki, Koichi
    Kakizawa, Nao
    Watanabe, Fumiaki
    Ichida, Kosuke
    Takayama, Yuji
    Fukui, Taro
    Hasegawa, Fumi
    Kikugawa, Rina
    Futsuhara, Kazushige
    Tsujinaka, Shingo
    Miyakura, Yasuyuki
    Noda, Hiroshi
    Rikiyama, Toshiki
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] TAS-102 in metastatic colorectal cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (01): : E18 - E18
  • [10] Efficacy and Safety of Regorafenib or TAS-102 in Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies
    Sueda, Toshinori
    Sakai, Daisuke
    Kudo, Toshihiro
    Sugiura, Takashi
    Takahashi, Hidekazu
    Haraguchi, Naotsugu
    Nishimura, Junichi
    Hata, Taishi
    Hayashi, Taro
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    Satoh, Taroh
    ANTICANCER RESEARCH, 2016, 36 (08) : 4299 - 4306
12345